Nrx pharmaceuticals announces improved survival at one year in highly comorbid covid-19 patients treated with zyesami (aviptadil)

Radnor, pa., sept. 27, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with covid-19 who were treated with zyesami™.
NRXP Ratings Summary
NRXP Quant Ranking